Venkatraman Seshan
Overview
Explore the profile of Venkatraman Seshan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
912
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El Daker S, Qualls D, Derkach A, Beqaj S, Boiocchi L, Seshan V, et al.
Haematologica
. 2025 Feb;
PMID: 39911114
Follicular lymphoma (FL) is an indolent B cell lymphoma with a heterogenous disease course, and patients may not require immediate treatment upon diagnosis. Scrutiny of its microenvironment may provide key...
2.
Arora A, Luo L, Kostrzewa C, Reiner A, Seshan V, Ernstoff M, et al.
bioRxiv
. 2024 Nov;
PMID: 39554118
Ideally, detection of somatic mutations in a tumor is accomplished using a patient-matched sample of normal cells as the benchmark. In this way somatic mutations can be distinguished from rare...
3.
Kim K, Alam S, Kuo F, Chen Z, Yip W, Katims A, et al.
Eur Urol
. 2024 Nov;
87(3):342-354.
PMID: 39550333
Background And Objective: Molecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed...
4.
Kumar A, Soumerai J, Soumerai J, Abramson J, Barnes J, Caron P, et al.
Blood
. 2024 Oct;
145(5):497-507.
PMID: 39437708
TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated patients...
5.
Qualls D, Lambert N, Caimi P, Merrill M, Pullarkat P, Godby R, et al.
Blood
. 2023 Sep;
142(26):2327-2331.
PMID: 37738563
In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and...
6.
Luttwak E, Noy A, Seshan V, Saltzman L, Greenberger L
Leuk Lymphoma
. 2023 Jun;
64(10):1727-1729.
PMID: 37384591
No abstract available.
7.
Orlow I, Sadeghi K, Edmiston S, Kenney J, Lezcano C, Wilmott J, et al.
PLoS One
. 2023 Apr;
18(4):e0269324.
PMID: 37011054
Introduction: We are conducting a multicenter study to identify classifiers predictive of disease-specific survival in patients with primary melanomas. Here we delineate the unique aspects, challenges, and best practices for...
8.
Sarfaty M, Golkaram M, Funt S, Al-Ahmadie H, Kaplan S, Song F, et al.
J Clin Oncol
. 2023 Mar;
41(17):3225-3235.
PMID: 36927002
Purpose: Immune checkpoint blockade (ICB) therapy has significantly improved clinical outcomes in bladder cancer. Identification of correlates of benefit is critical to select appropriate therapy for individual patients. Methods: To...
9.
Boucai L, Saqcena M, Kuo F, Grewal R, Socci N, Knauf J, et al.
Clin Cancer Res
. 2023 Feb;
29(8):1620-1630.
PMID: 36780190
Purpose: The determinants of response or resistance to radioiodine (RAI) are unknown. We aimed to identify genomic and transcriptomic factors associated with structural responses to RAI treatment of metastatic thyroid...
10.
Qualls D, Noy A, Straus D, Matasar M, Moskowitz C, Seshan V, et al.
Leuk Lymphoma
. 2023 Jan;
64(3):738-741.
PMID: 36642966
No abstract available.